Latest news ...
Some of our recent news articles.
Lilly, Avidity Biosciences Enter Global R&D Alliance
Lilly and Avidity Biosciences Announce Licensing and Research Collaboration
- Collaboration will pursue therapeutic targets focused on immunology and other indications
- Avidity to receive an upfront payment of $20 million and an investment of $15 million
- Avidity eligible to receive up to approximately $405 million per target in development and commercialization milestones, plus royalties
Read the full story »